Using PTFE mesh for breast reconstruction in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the use of polytetrafluoroethylene (PTFE) mesh in implant-based breast reconstruction for women diagnosed with early-stage breast cancer. It compares the efficacy and safety of PTFE mesh against allogeneic dura mater grafts, both of which are used to support breast implants. The study aims to determine if PTFE mesh can provide better outcomes in terms of complications and aesthetic results compared to traditional methods. Participants will be white women with breast cancer stages 0 to II who consent to the study and photographic documentation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* White women;
* Breast cancer stage 0-II;
* Indications for breast reconstruction;
* Consent to participate in the study and photographic documentation.

Exclusion Criteria:

* Non-white women;
* Breast cancer stage III-IV;
* Tubular breast;
* Mental and cognitive health disorders;
* Failure to comply with recommendations in the postoperative period (premature physical activity, not wearing compression underwear, missing scheduled visits, refusal of photo documentation);
* Patient refusal to participate in the study at any stage.

Where it's running

• The Branch of Hadassah Medical LTD
  Moscow, Skolkovo Innovation Center, Russia Recruiting

Study contacts

• Principal investigator: Alla Kartasheva, PhD — The Branch of Hadassah Medical LTD
• Study coordinator: Artem Mishin, MD
• Email: dr.mishin@mail.ru
• Phone: +7 (910) 175-98-75

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Capecitabine for MRD-positive, resected ER+/HER2-negative breast cancer

  This Phase 2 trial tests whether taking capecitabine can help people with resected, ER-positive/HER2-negative breast cancer who still have molecular residual disease after standard therapy.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT07631052

• Adding TheraBionic P1 radiofrequency therapy to treatment for early-stage HR+ HER2- breast cancer

  This study will try giving TheraBionic P1 amplitude-modulated radiofrequency therapy before surgery to see if it improves tumor response in women with early-stage, hormone receptor–positive, HER2-negative breast cancer.

  Recruiting at 8 sites Barbara Ann Karmanos Cancer Institute · Clarkston, Michigan and 7 other locations · NCT07218432

• Combining FWD1802 with CDK4/6 inhibitors or everolimus for ER+/HER2- advanced breast cancer

  This trial tests whether adding FWD1802 to CDK4/6 inhibitors or everolimus helps people with ER-positive/HER2-negative unresectable locally advanced or metastatic breast cancer who have progressed on or cannot use standard therapy.

  Recruiting Phase 1/2 Forward Pharmaceuticals Co., Ltd. · Shanghai · NCT07002177

• Predicting how hormone therapy before surgery affects breast cancer

  This study is testing how hormone therapy before surgery can help people with early-stage breast cancer and what it means for their tumors.

  Recruiting Phase 2 George Washington University · Washington D.C., District of Columbia · NCT06806930

• Meal timing during cancer treatment for Alaska Native and American Indian patients

  This test will see if an 8-hour time-restricted eating schedule during neoadjuvant or adjuvant therapy helps Alaska Native and American Indian adults with rectal or certain breast cancers.

  Recruiting Fred Hutchinson Cancer Center · Anchorage, Alaska · NCT06802172

• Decision-making tool to help women with early breast cancer choose treatment

  This project will test a patient decision aid to help women with early-stage breast cancer make treatment choices.

  Recruiting European Institute of Oncology · Milan, Italy · NCT06762496

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.